Invivyd Inc

Invivyd Inc

IVVD

Get informed when a big investor buys or sells

+ Follow
Market Cap$284.15M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Invivyd IncInvivyd Inc-2.4--59%--
$4.30

Current Fair Value

421.2% upside

Undervalued by 421.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$284.15 Million
Enterprise Value$132.46 Million
Dividend Yield$- (-)
Earnings per Share$-0.3
Beta0.71
Outstanding Shares320,435,078

Return

Return on Equity-59.27%ROE
Return on Assets-49.04%
Return on Invested Capital-60.10%

Valuation & Multiples

P/E Ratio-2.45P/E Ratio
PEG-1.21PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue2.27
Enterprise Value to EBIT-1.17
Enterprise Value to Net Income-2
Total Debt to Enterprise0.06
Debt to Equity0.05Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 19, 2026
EPS Estimate
$-0.08
Average shareholder expectation
Revenue Estimate
$20.06 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 5, 2026
EPS Estimate
$-0.11
Average shareholder expectation
Revenue Estimate
$15.04 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3663 22.50%
Total Calls561,000 19.97%
Total Puts205,500 50.42%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %73.13% 66.33%
Total Invested$294.24M 50.44%
Investors Holding146 25.00%

ESG Score

No data

About Invivyd Inc

2,021 employees

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antib...